Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to quiet chemo nerve pain

NCT ID NCT06848348

Symptom relief Sponsor: Dogwood Therapeutics Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 17, 2026 · Updated 3 times

Summary

This study tests an injected drug called Halneuron to see if it can safely reduce nerve pain caused by chemotherapy. About 240 adults who have nerve pain from platinum or taxane chemo will receive either Halneuron or a placebo shot. The goal is to measure pain relief, sleep, fatigue, and quality of life over several weeks, with an option for all participants to receive Halneuron later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Halneuron (injection)
What this could lead to
If it works, this could offer a new option to ease nerve pain caused by chemotherapy, improving daily comfort and quality of life for cancer survivors.
What could go wrong
This is an early Phase 2 trial with only 240 people, so results may not apply to everyone. The drug may not reduce pain better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients aged ≥18 years. * Neuropathic pain has been present and is attributed to platinum and/or taxane chemotherapy. * Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum and has no active or discernible disease progression. Exclusion Criteria: * Current neuropathic pain with symptoms similar to CINP but attributed to causes other than platinum or taxane chemotherapy. * Patients who have received HAL at any time prior to screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy induced neuropathic pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast neoplasm Cancer Pain chemotherapy-induced neuropathy colorectal neoplasm neoplasm neuralgia Pain peripheral nervous system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy induced neuropathic pain Chemotherapy induced pain Chemotherapy induced pain neuropathy

Contacts and locations

Locations

  • Central Recruiting Site

    Sheffield, Alabama, 35660, United States

  • Central Recruiting Site

    Glendale, Arizona, 85308, United States

  • Central Recruiting Site

    Phoenix, Arizona, 85022, United States

  • Central Recruiting Site

    Fair Oaks, California, 95628, United States

  • Central Recruiting Site

    Fountain Valley, California, 92708, United States

  • Central Recruiting Site

    Los Angeles, California, 91307, United States

  • Central Recruiting Site

    Santa Rosa, California, 95403, United States

  • Central Recruiting Site

    Wheat Ridge, Colorado, 80033, United States

  • Central Recruiting Site

    Jacksonville, Florida, 32205, United States

  • Central Recruiting Site

    Jacksonville, Florida, 32256, United States

  • Central Recruiting Site

    Lakeland, Florida, 33812, United States

  • Central Recruiting Site

    Orlando, Florida, 32832, United States

  • Central Recruiting Site

    Port Charlotte, Florida, 33952, United States

  • Central Recruiting Site

    Tampa, Florida, 33613, United States

  • Central Recruiting Site

    Gurnee, Illinois, 60031, United States

  • Central Recruiting Site

    Lake Charles, Louisiana, 70605, United States

  • Central Recruiting Site

    Fenton, Missouri, 63026, United States

  • Central Recruiting Site

    Las Vegas, Nevada, 89109, United States

  • Central Recruiting Site

    Garden City, New York, 11530, United States

  • Central Recruiting Site

    Williamsville, New York, 14221, United States

  • Central Recruiting Site

    Winston-Salem, North Carolina, 27103, United States

  • Central Recruiting Site

    Houston, Texas, 77346, United States

  • Central Recruiting Site

    McAllen, Texas, 78504, United States

  • Central Recruiting Site

    Salt Lake City, Utah, 84107, United States

  • Central Recruiting Site

    Madison, Wisconsin, 53715, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.